ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 109 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2021. The put-call ratio across all filers is 3.95 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,297,970 | -25.9% | 215,252 | +37.1% | 0.00% | – |
| Q1 2024 | $1,750,572 | +29.6% | 157,002 | +73.0% | 0.00% | – |
| Q4 2023 | $1,351,163 | +114.7% | 90,743 | -30.8% | 0.00% | – |
| Q3 2023 | $629,409 | -53.4% | 131,127 | -27.1% | 0.00% | – |
| Q2 2023 | $1,350,050 | +65.3% | 179,767 | -0.5% | 0.00% | – |
| Q1 2023 | $816,525 | -58.7% | 180,647 | +3.0% | 0.00% | – |
| Q4 2022 | $1,977,445 | +128389.0% | 175,461 | +9.2% | 0.00% | – |
| Q3 2022 | $1,539 | -23.2% | 160,746 | -35.1% | 0.00% | -100.0% |
| Q2 2022 | $2,004 | -99.9% | 247,743 | +15.5% | 0.00% | 0.0% |
| Q1 2022 | $3,625,000 | +21.2% | 214,486 | +54.2% | 0.00% | 0.0% |
| Q4 2021 | $2,990,000 | -75.2% | 139,138 | -14.6% | 0.00% | -66.7% |
| Q3 2021 | $12,039,000 | +61.5% | 162,996 | +19.6% | 0.00% | +50.0% |
| Q2 2021 | $7,455,000 | -60.1% | 136,333 | -46.2% | 0.00% | -60.0% |
| Q1 2021 | $18,684,000 | +64.7% | 253,385 | +92.5% | 0.01% | +66.7% |
| Q4 2020 | $11,346,000 | +3966.7% | 131,628 | +1683.3% | 0.00% | – |
| Q3 2020 | $279,000 | – | 7,381 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |